NCT06923098 PET/CT GUIDED BIOPSY VERSUS CT GUIDED BIOPSY IN EVALUATION OF SUSPECTED LUNG NEOPLASMS
| NCT ID | NCT06923098 |
| Status | Recruiting |
| Phase | — |
| Sponsor | All India Institute of Medical Sciences, Bhubaneswar |
| Condition | Lung Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 108 participants |
| Start Date | 2023-07-01 |
| Primary Completion | 2025-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 108 participants in total. It began in 2023-07-01 with a primary completion date of 2025-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Percutaneous CT guided biopsy is a well-established, standard sampling technique for suspected neoplastic lesions located in peripheral region in lung parenchyma. Inconclusive results on CT guided biopsy is substantially higher in large lung lesions which are prone to cause peripheral pneumonia, atelectasis and even regional necrosis, which are hard to be distinguished from tumor on CT images. Functional imaging guided biopsy like PET/CT guided biopsy identifies areas of highest concentration of neoplastic cells and provides accurate results. Only a few studies have been done regarding PET/CT guided biopsy and studies omparing PET/CT guided and CT guided percutaneous transthoracic lung biopsy are very few and this study would be a randomized trial comparing these diagnostic modalities in terms of diagnostic yield, diagnostic accuracy of sample and complications.
Eligibility Criteria
Inclusion Criteria: * Age above 18 years * INR \< 1.2 and platelet counts \> 80,000/mm3 * CT thorax with lung lesion more than 10 mm. * Accessible lesions for CT-guided biopsy. Exclusion Criteria: * Participants with pre-existing bleeding diathesis like hemophilia, coagulopathy defined by -INR ≥1.2 and Platelet counts ≤ 80,000/mm3 * Participants who refuse to provide consent * Signs of hypoperfusion like hypotension, cyanosis etc. * Presence of hypoxemia with SpO2 \< 94 %- measured in a pulse oximeter) * Pregnant/Lactating female subjects * Non-cooperative subjects * Lesions that are inaccessible (decision made on pre-biopsy planning) * Serum creatinine level more than 2mg/dl.
Frequently Asked Questions
Who can join the NCT06923098 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06923098 currently recruiting?
Yes, NCT06923098 is actively recruiting participants. Visit ClinicalTrials.gov or contact All India Institute of Medical Sciences, Bhubaneswar to inquire about joining.
Where is the NCT06923098 trial being conducted?
This trial is being conducted at Bhubaneswar, India.
Who is sponsoring the NCT06923098 clinical trial?
NCT06923098 is sponsored by All India Institute of Medical Sciences, Bhubaneswar. The trial plans to enroll 108 participants.